Back to top
more

Innoviva (INVA)

(Delayed Data from NSDQ)

$14.69 USD

14.69
636,366

+0.21 (1.45%)

Updated Apr 18, 2024 04:00 PM ET

After-Market: $14.70 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises

J&J (JNJ) beats estimates for first-quarter earnings and sales. It raises full-year sales and earnings guidance.

Is Innoviva (INVA) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Will J&J (JNJ) Pharma Unit Outperform Market & Drive Q1 Results?

In J&J's (JNJ) Pharma segment, its oncology drug, Darzalex as well as a psoriasis treatment, Stelara is likely to have driven sales growth in the first quarter

Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance

Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.

Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy

Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs

FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.

J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits

To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.

AstraZeneca (AZN) Ultomiris Gets CHMP Nod for New Rare Disease

CHMP recommends AstraZeneca's (AZN) Ultomiris for the treatment of patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

Novartis (NVS) Gets CHMP Positive Opinion for Entresto Approval

Novartis (NVS) receives a positive opinion from the CHMP for Entresto (sacubitril/valsartan) for a new indication in pediatric patients.

Innoviva (INVA) Gains As Market Dips: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $13.27, marking a +0.15% move from the previous day.

Innoviva (INVA) Stock Moves -1.06%: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $13.03, marking a -1.06% move from the previous day.

Innoviva (INVA) Gains As Market Dips: What You Should Know

Innoviva (INVA) closed at $13.47 in the latest trading session, marking a +1.43% move from the prior day.

Innoviva (INVA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Innoviva (INVA) closed at $12.77, marking a -1.47% move from the previous day.

John Blank headshot

Did a Move to Buy Global Stocks Happen? Zacks DEC Market Strategy

A comprehensive look ahead to a calendar 2023 trading year that has more questions than answers at this point.

Should Value Investors Buy Innoviva (INVA) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks.com featured highlights PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure

PBF Energy, Innoviva, Global Partners, Heritage-Crystal Clean and Sterling Infrastructure have been highlighted in this Screen of The Week article.

Anindya Barman headshot

5 Value Stocks With Attractive EV-to-EBITDA Ratios to Snap Up

We have screened value stocks PBF, INVA, GLP, HCCI and STRL based on the EV-to-EBITDA ratio, which offers a clearer picture of valuation and earnings potential.

Are Investors Undervaluing Innoviva (INVA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Innoviva (INVA) Q3 Earnings and Revenues Lag Estimates

Innoviva (INVA) delivered earnings and revenue surprises of -78.18% and 81.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q3 Earnings and Revenues Beat Estimates

Lilly (LLY) delivered earnings and revenue surprises of 0.51% and 0.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Bayer (BAYRY) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Innoviva (INVA) Earnings Expected to Grow: Should You Buy?

Innoviva (INVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.